{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:57:44Z","timestamp":1779231464817,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin's lymphoma. Patients become progressively refractory to conventional chemotherapy, and their prognosis is poor. However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.<\/jats:p>\n          <jats:p>Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months. In this case, lymph node biopsies were performed before and six months after temsirolimus therapy. Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells. Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression. Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy. Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.<\/jats:p>\n          <jats:p>This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.<\/jats:p>","DOI":"10.1186\/1756-8722-3-30","type":"journal-article","created":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T18:14:09Z","timestamp":1284056049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma"],"prefix":"10.1186","volume":"3","author":[{"given":"Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Varna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Xiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Janin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,9]]},"reference":[{"key":"114_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1046\/j.1365-2141.2003.04761.x","volume":"124","author":"F Bertoni","year":"2004","unstructured":"Bertoni F, Zucca E, Cotter FE: Molecular basis of mantle cell lymphoma. Br J Haematol. 2004, 124: 130-140. 10.1046\/j.1365-2141.2003.04761.x.","journal-title":"Br J Haematol"},{"key":"114_CR2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Seto M, Muller-Hermelink HK: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008, Lyon: International agency for research on cancer, 4","edition":"4"},{"key":"114_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","volume":"114","author":"M Ghielmini","year":"2009","unstructured":"Ghielmini M, Zucca E: How I treat mantle cell lymphoma. Blood. 2009, 114: 1469-1476. 10.1182\/blood-2009-02-179739.","journal-title":"Blood"},{"issue":"1","key":"114_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/leu.2009.223","volume":"24","author":"WL Zhao","year":"2010","unstructured":"Zhao WL: Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia. 2010, 24 (1): 13-21. 10.1038\/leu.2009.223. Epub 2009 Oct 29. Review","journal-title":"Leukemia"},{"key":"114_CR5","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","volume":"111","author":"J Dal Col","year":"2008","unstructured":"Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni M, Pavan A, Spina M, Bergamin S, Rizzo S, Tirelli U: Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood. 2008, 111: 5142-5151. 10.1182\/blood-2007-07-103481.","journal-title":"Blood"},{"key":"114_CR6","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005, 23: 5347-5356. 10.1200\/JCO.2005.13.466.","journal-title":"J Clin Oncol"},{"key":"114_CR7","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009, 27: 3822-3829. 10.1200\/JCO.2008.20.7977.","journal-title":"J Clin Oncol"},{"key":"114_CR8","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999, 17: 1244-","journal-title":"J Clin Oncol"},{"key":"114_CR9","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/blood-2006-06-030833","volume":"109","author":"Z Zeng","year":"2007","unstructured":"Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Konopleva M: Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007, 109: 3509-3512. 10.1182\/blood-2006-06-030833.","journal-title":"Blood"},{"key":"114_CR10","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","volume":"66","author":"D Del Bufalo","year":"2006","unstructured":"Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M: Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006, 66: 5549-5554. 10.1158\/0008-5472.CAN-05-2825.","journal-title":"Cancer Res"},{"key":"114_CR11","first-page":"143","volume":"87","author":"CM Derks","year":"1977","unstructured":"Derks CM, Jacobovitz-Derks D: Embolic pneumopathy induced by oleic acid. A systematic morphologic study. Am J Pathol. 1977, 87: 143-158.","journal-title":"Am J Pathol"},{"key":"114_CR12","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/blood-2004-09-3540","volume":"105","author":"M Guba","year":"2005","unstructured":"Guba M, Yezhelyev M, Eichhorn ME, Schmid G, Ischenko I, Papyan A, Graeb C, Seeliger H, Geissler EK, Jauch KW, Bruns CJ: Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 2005, 105: 4463-4469. 10.1182\/blood-2004-09-3540.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-3-30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:39:12Z","timestamp":1630471152000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-3-30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,9]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["114"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-3-30","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,9]]},"assertion":[{"value":"31 May 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"30"}}